David J. Wambeke, Chief Business Officer at DiaMedica Therapeutics Inc. (DMAC), bought 20,000 shares at $2.46 ($49K) on 2023-11-16, disclosed to the SEC on 2023-11-16.
Open-market purchase of $49k DMAC by Chief Business Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| DMAC | BUY | 2023-06-26 | $300K | — | Filing → |
| DMAC | BUY | 2023-04-11 | $750K | — | Filing → |